Up­sized of­fer­ing de­liv­ers $100M pay­off to ar­genx as an­oth­er biotech joins the IPO pa­rade

The Dutch an­ti­body shop ar­genx is the lat­est biotech to join the grow­ing IPO pa­rade on Nas­daq.

The biotech raised $100 mil­lion on the sale of 5.9 mil­lion shares at $17 each. And that re­flects an in­crease of more than 2 mil­lion shares over what the com­pa­ny had ini­tial­ly planned to of­fer.

Ar­genx will trade un­der the ARGX sym­bol and CEO Tim Van Hauw­er­meiren gets to ring the open­ing bell to­day to cel­e­brate the IPO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER